Coya Therapeutics 2025 Q3 Earnings 47.4% Net Loss Reduction Drives Optimism

Coya Therapeutics (COYA) reported fiscal 2025 Q3 earnings on Nov 13, 2025, with total revenue flat at $3.56 million compared to $0 in 2024 Q3. The company narrowed its net loss to $2.12 million (down 47.4%) and reduced its per-share loss to $0.13 (a 50% improvement). Recent financial progress aligns with clinical advancements and a $23 million capital raise, extending cash runway into 2027.

Revenue

Coya Therapeutics reported $3.56 million in total revenue for 2025 Q3, driven entirely by collaboration revenue. This marked a 0.0% year-over-year increase from the $0 recorded in the prior-year period. The absence of revenue diversification into other segments underscores the company’s current reliance on partnership-driven income.

Earnings/Net Income

The company narrowed its net loss to $2.12 million in 2025 Q3, a 47.4% reduction from the $4.02 million loss in 2024 Q3. Earnings per share (EPS) improved to -$0.13 from -$0.26, reflecting enhanced cost management and collaboration revenue recognition. The 50% improvement in EPS and 47.4% reduction in net loss signal positive progress in financial stability despite ongoing R&D expenditures.

Price Action

The stock price of Coya Therapeutics edged up 0.83% during the latest trading day, climbed 5.55% during the most recent full trading week, and rose 0.50% month-to-date.

Post-Earnings Price Action Review

Coya Therapeutics’ stock has shown modest post-earnings strength, with a 0.83% single-day gain and a 5.55% weekly rally. The 0.50% month-to-date increase suggests investor confidence in the company’s clinical milestones and financial improvements. While the upward trajectory remains modest, the stock’s performance aligns with broader biotech sector optimism and the company’s progress in neurodegenerative disease therapies.

CEO Commentary

Coya Therapeutics’ CEO, Arun Swaminathan, highlighted the company’s “significant strides in advancing its Treg-enhancing therapies and reducing financial losses.” He emphasized the $23 million capital raise as a “critical milestone” extending operational runway and enabling continued R&D in ALS and frontotemporal dementia. Swaminathan expressed cautious optimism about the $4.2 million milestone payment from Dr. Reddy’s and the upcoming NEALS-affiliated ALSTARS Trial, underscoring the company’s focus on clinical validation and strategic partnerships.

Guidance

The company did not provide explicit forward-looking financial guidance in its Q3 report. However, it outlined key catalysts, including the initiation of the ALSTARS Trial, potential $4.2 million milestone payments, and IND submission for FTD in Q4 2025. These milestones are expected to drive future revenue and operational efficiency.

Additional News

Coya Therapeutics secured a $23 million public offering, extending cash reserves to fund operations through 2027. The FDA accepted the IND application for COYA 302 in ALS, triggering a $4.2 million milestone payment from Dr. Reddy’s. Additionally, the company launched the NEALS-affiliated ALSTARS Trial, a pivotal Phase 2 study for ALS, and reported preclinical data showing COYA 303’s CNS anti-inflammatory effects. These developments position Coya to leverage milestone-driven funding and advance its neurodegenerative disease pipeline.